Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ventripoint Announces Sponsorship for the European Society of Cardiology Congress 2022



Ventripoint Diagnostics Ltd.

Toronto, Ontario – TheNewswire – August 26, 2022 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is excited to announce that it will be exhibiting at the 70th European Society of Cardiology (ESC) Congress, which will be held in Barcelona, Spain from August 26-29, 2022

The spotlight in 2022 is “Cardiac imaging”, ever more important in cardiovascular medicine with its profound implications from prevention to diagnosis, clinical decision-making, guiding of interventions and follow-up of therapeutic procedures.

The Congress website ( reports 40,000 participants from 170 countries will hear 5,000 medical presentations during the congress. For the first time, the ESC Conference will be held virtually and in person, providing access to the latest cardiology research and clinical updates from anywhere in the world.

The ESC is comprised of clinicians, scientists, and other professionals in the cardiology field. The ESC aims to unite national cardiac societies from around the world to further study and understand cardiovascular disease.

This is another opportunity for Ventripoint to inform the cardiology community about its innovative VMS+ products and follows on the heels of the successful AEPC conference this past May in Geneva (see NR May 17, 2022) and the ASE conference in June in Seattle (see NR June 7, 2022). In addition to Ventripoint’s direct sales team, our European distributor for Europe, AngioPro, will be joining us in the exhibition booth to connect with new potential customers and existing users.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS+ products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Copyright (c) 2022 TheNewswire - All rights reserved.